Chimenti S - Search Results

1

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.

Galluzzo M, Boca AN, Botti E, Potenza C, Malara G, Malagoli P, Vesa S, Chimenti S, Buzoianu AD, Talamonti M, Costanzo A. Galluzzo M, et al. Among authors: chimenti s. Dermatology. 2016;232(2):230-6. doi: 10.1159/000441719. Epub 2015 Dec 18. Dermatology. 2016. PMID: 26678060

2

Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.

Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M, Chimenti S. Costanzo A, et al. Among authors: chimenti ms, chimenti s. Dermatology. 2009;218(2):146-50. doi: 10.1159/000168086. Epub 2008 Oct 30. Dermatology. 2009. PMID: 18971577

3

Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.

Talamonti M, Galluzzo M, Chiricozzi A, Teoli M, Bavetta M, Costanzo A, Chimenti S. Talamonti M, et al. Among authors: chimenti s. J Drugs Dermatol. 2012 Aug;11(8):1000-2. J Drugs Dermatol. 2012. PMID: 22859249

4

Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.

Boca AN, Talamonti M, Galluzzo M, Botti E, Vesa SC, Chimenti S, Buzoianu AD, Costanzo A. Boca AN, et al. Among authors: chimenti s. Immunol Lett. 2013 Nov-Dec;156(1-2):127-31. doi: 10.1016/j.imlet.2013.09.028. Epub 2013 Oct 17. Immunol Lett. 2013. PMID: 24140476

5

Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.

Saraceno R, Talamonti M, Galluzzo M, Chiricozzi A, Costanzo A, Chimenti S. Saraceno R, et al. Among authors: chimenti s. Case Rep Dermatol. 2013 Sep 26;5(3):254-9. doi: 10.1159/000348645. eCollection 2013. Case Rep Dermatol. 2013. PMID: 24163658 Free PMC article.

6

What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.

Talamonti M, Galluzzo M, Bianchi L, Boca AN, Costanzo A, Chimenti S. Talamonti M, et al. Among authors: chimenti s. Dermatology. 2014;229(4):324-32. doi: 10.1159/000365077. Epub 2014 Nov 15. Dermatology. 2014. PMID: 25402662

7

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.

Talamonti M, Galluzzo M, Chimenti S, Costanzo A. Talamonti M, et al. Among authors: chimenti s. J Am Acad Dermatol. 2016 Feb;74(2):374-5. doi: 10.1016/j.jaad.2015.08.055. J Am Acad Dermatol. 2016. PMID: 26775778 No abstract available.

8

Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.

Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S. Costanzo A, et al. Among authors: chimenti s. Dermatology. 2009;219(1):48-53. doi: 10.1159/000213758. Epub 2009 Apr 16. Dermatology. 2009. PMID: 19372639

9

Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.

Talamonti M, Teoli M, Botti E, Spallone G, Chimenti S, Costanzo A. Talamonti M, et al. Among authors: chimenti s. Dermatology. 2011;222(3):250-5. doi: 10.1159/000326111. Epub 2011 Apr 13. Dermatology. 2011. PMID: 21494026

10

Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.

Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, Chimenti S, Costanzo A. Talamonti M, et al. Among authors: chimenti s. Br J Dermatol. 2013 Aug;169(2):458-63. doi: 10.1111/bjd.12331. Br J Dermatol. 2013. PMID: 23521149

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

433 results

Search Page

Filters